-
2
-
-
79957501125
-
Human cancers express mutator phenotypes: origin, consequences and targeting
-
Loeb LA Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011, 11:450-457.
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 450-457
-
-
Loeb, L.A.1
-
3
-
-
57149118627
-
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia
-
Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
-
(2008)
Science
, vol.322
, pp. 1377-1380
-
-
Mullighan, C.G.1
Phillips, L.A.2
Su, X.3
-
4
-
-
77951139631
-
Genome remodelling in a basal-like breast cancer metastasis and xenograft
-
Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
-
(2010)
Nature
, vol.464
, pp. 999-1005
-
-
Ding, L.1
Ellis, M.J.2
Li, S.3
-
5
-
-
70349969478
-
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
-
Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
-
(2009)
Nature
, vol.461
, pp. 809-813
-
-
Shah, S.P.1
Morin, R.D.2
Khattra, J.3
-
6
-
-
78751644099
-
Genetic variegation of clonal architecture and propagating cells in leukaemia
-
Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
-
(2011)
Nature
, vol.469
, pp. 356-361
-
-
Anderson, K.1
Lutz, C.2
van Delft, F.W.3
-
7
-
-
77949809850
-
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas
-
Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010, 220:562-573.
-
(2010)
J Pathol
, vol.220
, pp. 562-573
-
-
Geyer, F.C.1
Weigelt, B.2
Natrajan, R.3
-
9
-
-
12944329959
-
Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity
-
Gisselsson D, Pettersson L, Hoglund M, et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci USA 2000, 97:5357-5362.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 5357-5362
-
-
Gisselsson, D.1
Pettersson, L.2
Hoglund, M.3
-
10
-
-
78049380554
-
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
-
Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
-
(2010)
Nature
, vol.467
, pp. 1109-1113
-
-
Campbell, P.J.1
Yachida, S.2
Mudie, L.J.3
-
11
-
-
78049398107
-
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
-
Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
-
(2010)
Nature
, vol.467
, pp. 1114-1117
-
-
Yachida, S.1
Jones, S.2
Bozic, I.3
-
12
-
-
73649102105
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
-
Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
-
(2010)
Cancer Cell
, vol.17
, pp. 77-88
-
-
Turke, A.B.1
Zejnullahu, K.2
Wu, Y.L.3
-
13
-
-
79953118839
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
-
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
-
(2011)
Sci Transl Med
, vol.3
-
-
Sequist, L.V.1
Waltman, B.A.2
Dias-Santagata, D.3
-
14
-
-
56749098278
-
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
-
Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26:5352-5359.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5352-5359
-
-
Heinrich, M.C.1
Maki, R.G.2
Corless, C.L.3
-
15
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
-
(2002)
Cancer Cell
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
-
16
-
-
75549083303
-
Tumor heterogeneity: causes and consequences
-
Marusyk A, Polyak K Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010, 1805:105-117.
-
(2010)
Biochim Biophys Acta
, vol.1805
, pp. 105-117
-
-
Marusyk, A.1
Polyak, K.2
-
17
-
-
77958014613
-
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
-
Gerlinger M, Swanton C How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-1143.
-
(2010)
Br J Cancer
, vol.103
, pp. 1139-1143
-
-
Gerlinger, M.1
Swanton, C.2
-
18
-
-
51349126920
-
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
-
Campbell PJ, Pleasance ED, Stephens PJ, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 2008, 105:13081-13086.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 13081-13086
-
-
Campbell, P.J.1
Pleasance, E.D.2
Stephens, P.J.3
-
19
-
-
78751661556
-
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells
-
Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
-
(2011)
Nature
, vol.469
, pp. 362-367
-
-
Notta, F.1
Mullighan, C.G.2
Wang, J.C.3
-
20
-
-
33947101019
-
Patterns of somatic mutation in human cancer genomes
-
Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
-
(2007)
Nature
, vol.446
, pp. 153-158
-
-
Greenman, C.1
Stephens, P.2
Smith, R.3
-
21
-
-
74449085934
-
A small-cell lung cancer genome with complex signatures of tobacco exposure
-
Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
-
(2010)
Nature
, vol.463
, pp. 184-190
-
-
Pleasance, E.D.1
Stephens, P.J.2
O'Meara, S.3
-
22
-
-
77249123407
-
Signatures of mutation and selection in the cancer genome
-
Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463:893-898.
-
(2010)
Nature
, vol.463
, pp. 893-898
-
-
Bignell, G.R.1
Greenman, C.D.2
Davies, H.3
-
24
-
-
74449093973
-
A comprehensive catalogue of somatic mutations from a human cancer genome
-
Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
-
(2010)
Nature
, vol.463
, pp. 191-196
-
-
Pleasance, E.D.1
Cheetham, R.K.2
Stephens, P.J.3
-
25
-
-
79952264848
-
A non-genetic route to aneuploidy in human cancers
-
Krajcovic M, Johnson NB, Sun Q, et al. A non-genetic route to aneuploidy in human cancers. Nat Cell Biol 2011, 13:324-330.
-
(2011)
Nat Cell Biol
, vol.13
, pp. 324-330
-
-
Krajcovic, M.1
Johnson, N.B.2
Sun, Q.3
-
26
-
-
80051871652
-
Aneuploidy drives genomic instability in yeast
-
Sheltzer JM, Blank HM, Pfau SJ, et al. Aneuploidy drives genomic instability in yeast. Science 2011, 333:1026-1030.
-
(2011)
Science
, vol.333
, pp. 1026-1030
-
-
Sheltzer, J.M.1
Blank, H.M.2
Pfau, S.J.3
-
27
-
-
80051874823
-
Mutational inactivation of STAG2 causes aneuploidy in human cancer
-
Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011, 333:1039-1043.
-
(2011)
Science
, vol.333
, pp. 1039-1043
-
-
Solomon, D.A.1
Kim, T.2
Diaz-Martinez, L.A.3
-
28
-
-
17244367849
-
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
-
Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
-
(2005)
Nature
, vol.434
, pp. 864-870
-
-
Bartkova, J.1
Horejsi, Z.2
Koed, K.3
-
29
-
-
33845235459
-
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
-
Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
-
(2006)
Nature
, vol.444
, pp. 633-637
-
-
Bartkova, J.1
Rezaei, N.2
Liontos, M.3
-
30
-
-
78650959663
-
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
-
Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
-
(2011)
Cell
, vol.144
, pp. 27-40
-
-
Stephens, P.J.1
Greenman, C.D.2
Fu, B.3
-
31
-
-
77953658106
-
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
-
Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009, 1:323-337.
-
(2009)
EMBO Mol Med
, vol.1
, pp. 323-337
-
-
Martin, S.A.1
McCarthy, A.2
Barber, L.J.3
-
32
-
-
79953283356
-
Genetic interactions in cancer progression and treatment
-
Ashworth A, Lord CJ, Reis-Filho JS Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
-
(2011)
Cell
, vol.145
, pp. 30-38
-
-
Ashworth, A.1
Lord, C.J.2
Reis-Filho, J.S.3
-
33
-
-
0036682481
-
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
-
Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
-
(2002)
Blood
, vol.100
, pp. 1014-1018
-
-
Roche-Lestienne, C.1
Soenen-Cornu, V.2
Grardel-Duflos, N.3
-
34
-
-
59749086693
-
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense
-
Negri T, Pavan GM, Virdis E, et al. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense. J Natl Cancer Inst 2009, 101:194-204.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 194-204
-
-
Negri, T.1
Pavan, G.M.2
Virdis, E.3
-
35
-
-
72949119310
-
Complex landscapes of somatic rearrangement in human breast cancer genomes
-
Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010.
-
(2009)
Nature
, vol.462
, pp. 1005-1010
-
-
Stephens, P.J.1
McBride, D.J.2
Lin, M.L.3
-
36
-
-
67650434696
-
Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma
-
Klein CA, Stoecklein NH Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res 2009, 69:5285-5288.
-
(2009)
Cancer Res
, vol.69
, pp. 5285-5288
-
-
Klein, C.A.1
Stoecklein, N.H.2
-
37
-
-
33748286796
-
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
-
Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006, 38:1043-1048.
-
(2006)
Nat Genet
, vol.38
, pp. 1043-1048
-
-
Carter, S.L.1
Eklund, A.C.2
Kohane, I.S.3
Harris, L.N.4
Szallasi, Z.5
-
38
-
-
42949150219
-
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer
-
Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008, 13:441-453.
-
(2008)
Cancer Cell
, vol.13
, pp. 441-453
-
-
Stoecklein, N.H.1
Hosch, S.B.2
Bezler, M.3
-
39
-
-
79956160582
-
Paradoxical relationship between chromosomal instability and survival outcome in cancer
-
Birkbak NJ, Eklund AC, Li Q, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011, 71:3447-3452.
-
(2011)
Cancer Res
, vol.71
, pp. 3447-3452
-
-
Birkbak, N.J.1
Eklund, A.C.2
Li, Q.3
-
40
-
-
0001641514
-
Mutations of bacteria from virus sensitivity to virus resistance
-
Luria SE, Delbruck M Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28:491-511.
-
(1943)
Genetics
, vol.28
, pp. 491-511
-
-
Luria, S.E.1
Delbruck, M.2
-
41
-
-
77954740501
-
Metastatic behavior of breast cancer subtypes
-
Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3271-3277
-
-
Kennecke, H.1
Yerushalmi, R.2
Woods, R.3
-
43
-
-
69249087671
-
Environment-mediated drug resistance: a major contributor to minimal residual disease
-
Meads MB, Gatenby RA, Dalton WS Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 665-674
-
-
Meads, M.B.1
Gatenby, R.A.2
Dalton, W.S.3
-
45
-
-
77953066865
-
The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures
-
Krause S, Maffini MV, Soto AM, Sonnenschein C The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 2010, 10:263.
-
(2010)
BMC Cancer
, vol.10
, pp. 263
-
-
Krause, S.1
Maffini, M.V.2
Soto, A.M.3
Sonnenschein, C.4
-
46
-
-
0035499267
-
Stem cells, cancer, and cancer stem cells
-
Reya T, Morrison SJ, Clarke MF, Weissman IL Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
-
(2001)
Nature
, vol.414
, pp. 105-111
-
-
Reya, T.1
Morrison, S.J.2
Clarke, M.F.3
Weissman, I.L.4
-
47
-
-
33750313208
-
Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells
-
Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
-
(2006)
Cancer Res
, vol.66
, pp. 9339-9344
-
-
Clarke, M.F.1
Dick, J.E.2
Dirks, P.B.3
-
48
-
-
84855332744
-
Breast cancer stem cells: beyond semantics
-
Badve S, Nakshatri H Breast cancer stem cells: beyond semantics. Lancet Oncol 2012, 13:e43-e48.
-
(2012)
Lancet Oncol
, vol.13
-
-
Badve, S.1
Nakshatri, H.2
-
49
-
-
57349143739
-
Efficient tumour formation by single human melanoma cells
-
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
-
(2008)
Nature
, vol.456
, pp. 593-598
-
-
Quintana, E.1
Shackleton, M.2
Sabel, M.S.3
Fullen, D.R.4
Johnson, T.M.5
Morrison, S.J.6
-
50
-
-
79956351015
-
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
-
Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011, 108:7950-7955.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 7950-7955
-
-
Chaffer, C.L.1
Brueckmann, I.2
Scheel, C.3
-
51
-
-
80051967505
-
Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells
-
Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
-
(2011)
Cell
, vol.146
, pp. 633-644
-
-
Gupta, P.B.1
Fillmore, C.M.2
Jiang, G.3
-
52
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
-
(2006)
Cancer Res
, vol.66
, pp. 1500-1508
-
-
O'Reilly, K.E.1
Rojo, F.2
She, Q.B.3
-
53
-
-
51349164790
-
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
-
Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
-
(2008)
J Clin Invest
, vol.118
, pp. 3065-3074
-
-
Carracedo, A.1
Ma, L.2
Teruya-Feldstein, J.3
-
54
-
-
77956579297
-
A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors
-
abstr 3008.
-
Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 3008.
-
(2010)
Proc Am Soc Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Di Cosimo, S.1
Bendell, J.C.2
Cervantes-Ruiperez, A.3
-
55
-
-
77950809059
-
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
-
Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
-
(2010)
Cell
, vol.141
, pp. 69-80
-
-
Sharma, S.V.1
Lee, D.Y.2
Li, B.3
-
56
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
-
57
-
-
24944497744
-
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
-
Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5900-5909
-
-
Eberhard, D.A.1
Johnson, B.E.2
Amler, L.C.3
-
58
-
-
50249092801
-
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
-
Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216:64-74.
-
(2008)
J Pathol
, vol.216
, pp. 64-74
-
-
Liegl, B.1
Kepten, I.2
Le, C.3
-
59
-
-
78349265779
-
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer
-
Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010, 16:5489-5498.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5489-5498
-
-
Suda, K.1
Murakami, I.2
Katayama, T.3
-
60
-
-
78649436372
-
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
-
Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010, 3:ra84.
-
(2010)
Sci Signal
, vol.3
-
-
Corcoran, R.B.1
Dias-Santagata, D.2
Bergethon, K.3
Iafrate, A.J.4
Settleman, J.5
Engelman, J.A.6
-
61
-
-
80051625929
-
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
-
Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011, 29:3085-3096.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3085-3096
-
-
Wagle, N.1
Emery, C.2
Berger, M.F.3
-
62
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
-
63
-
-
39849097680
-
Resistance to therapy caused by intragenic deletion in BRCA2
-
Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
-
(2008)
Nature
, vol.451
, pp. 1111-1115
-
-
Edwards, S.L.1
Brough, R.2
Lord, C.J.3
-
64
-
-
80051642095
-
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas
-
Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011, 29:3008-3015.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3008-3015
-
-
Norquist, B.1
Wurz, K.A.2
Pennil, C.C.3
-
65
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
-
66
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
-
(2006)
N Engl J Med
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
-
67
-
-
3142676436
-
Overriding imatinib resistance with a novel ABL kinase inhibitor
-
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
-
(2004)
Science
, vol.305
, pp. 399-401
-
-
Shah, N.P.1
Tran, C.2
Lee, F.Y.3
Chen, P.4
Norris, D.5
Sawyers, C.L.6
-
68
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
-
(2001)
N Engl J Med
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
-
69
-
-
79960435101
-
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer
-
Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011, 17:4901-4914.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4901-4914
-
-
Molinari, F.1
Felicioni, L.2
Buscarino, M.3
-
70
-
-
80051965827
-
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer
-
Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:3316-3321.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3316-3321
-
-
Zhou, Q.1
Zhang, X.C.2
Chen, Z.H.3
-
71
-
-
70349254450
-
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
-
Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009, 114:2168-2171.
-
(2009)
Blood
, vol.114
, pp. 2168-2171
-
-
Soverini, S.1
Gnani, A.2
Colarossi, S.3
-
72
-
-
66149098947
-
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
-
Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69:2912-2918.
-
(2009)
Cancer Res
, vol.69
, pp. 2912-2918
-
-
Attard, G.1
Swennenhuis, J.F.2
Olmos, D.3
-
73
-
-
67349257845
-
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
-
Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
-
(2009)
Nat Med
, vol.15
, pp. 559-565
-
-
Liu, W.1
Laitinen, S.2
Khan, S.3
-
74
-
-
24744443720
-
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy
-
Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106:2128-2137.
-
(2005)
Blood
, vol.106
, pp. 2128-2137
-
-
Willis, S.G.1
Lange, T.2
Demehri, S.3
-
75
-
-
77955911497
-
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
-
Inda MM, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010, 24:1731-1745.
-
(2010)
Genes Dev
, vol.24
, pp. 1731-1745
-
-
Inda, M.M.1
Bonavia, R.2
Mukasa, A.3
-
76
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
77
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
78
-
-
33845311843
-
Human cancers express a mutator phenotype
-
Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 2006, 103:18238-18242.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 18238-18242
-
-
Bielas, J.H.1
Loeb, K.R.2
Rubin, B.P.3
True, L.D.4
Loeb, L.A.5
-
79
-
-
52949116364
-
The role of cytoreductive/debulking surgery in ovarian cancer
-
quiz 11.
-
Wakabayashi MT, Lin PS, Hakim AA The role of cytoreductive/debulking surgery in ovarian cancer. J Natl Compr Canc Netw 2008, 6:803-810. quiz 11.
-
(2008)
J Natl Compr Canc Netw
, vol.6
, pp. 803-810
-
-
Wakabayashi, M.T.1
Lin, P.S.2
Hakim, A.A.3
-
80
-
-
78650387260
-
CyberKnife stereotactic radiosurgery for intracranial neoplasms, with a focus on malignant tumors
-
Bucholz RD, Laycock KA, Cuff LE CyberKnife stereotactic radiosurgery for intracranial neoplasms, with a focus on malignant tumors. Technol Cancer Res Treat 2010, 9:541-550.
-
(2010)
Technol Cancer Res Treat
, vol.9
, pp. 541-550
-
-
Bucholz, R.D.1
Laycock, K.A.2
Cuff, L.E.3
-
81
-
-
33646256145
-
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
-
Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006, 66:3987-3991.
-
(2006)
Cancer Res
, vol.66
, pp. 3987-3991
-
-
Hunter, C.1
Smith, R.2
Cahill, D.P.3
-
82
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
-
83
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.W.2
Issaragrisil, S.3
-
84
-
-
0037206022
-
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer
-
Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002, 360:683-689.
-
(2002)
Lancet
, vol.360
, pp. 683-689
-
-
Klein, C.A.1
Blankenstein, T.J.2
Schmidt-Kittler, O.3
|